drugset / Trial / NCT07224477

A Clinical Study of V540A in Healthy Female Participants (V540A-005)

NCT07224477

Phase 2 Not yet recruiting 525 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupTriple-blindPrevention

Summary

Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. A standard vaccine to prevent HPV-related cancers is V503. V503 protects against 9 types of HPV. V540A is a study vaccine designed to protect against the same (shared) 9 HPV types plus other (unique) HPV types. Researchers want to learn if V540A: * Is safe and if people tolerate it * Works as well as V503 to cause an immune response (the body's response to protect against infections and illnesses) to the shared HPV types.

Timeline

Start
2026-07-20
Primary completion
2028-04-04
Completion
2028-04-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gardasil 9 Vaccine Intramuscular
Subject V540A-2 Unknown Intramuscular
Subject V540A-3 Unknown Intramuscular

Indications

No indication recorded.